Drugs / JNJ-95475939
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06881251 | Feb 2025 → Mar 2026 | atopic eczema | Janssen Research & Development, LLC | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-95475939 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06881251 ↗ |
| Route | Subcutaneous | “JNJ-95475939 will be administered subcutaneously.” NCT06881251 ↗ |